These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12404558

  • 1. Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.
    Patat A, Paty I, Hindmarch I.
    Hum Psychopharmacol; 2001 Jul; 16(5):369-392. PubMed ID: 12404558
    [Abstract] [Full Text] [Related]

  • 2. Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening.
    Hindmarch I, Patat A, Stanley N, Paty I, Rigney U.
    Hum Psychopharmacol; 2001 Mar; 16(2):159-167. PubMed ID: 12404586
    [Abstract] [Full Text] [Related]

  • 3. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
    Leufkens TR, Lund JS, Vermeeren A.
    J Sleep Res; 2009 Dec; 18(4):387-96. PubMed ID: 19552733
    [Abstract] [Full Text] [Related]

  • 4. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia.
    Drake CL, Roehrs TA, Mangano RM, Roth T.
    Hum Psychopharmacol; 2000 Dec; 15(8):595-604. PubMed ID: 12404612
    [Abstract] [Full Text] [Related]

  • 5. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
    Otmani S, Demazières A, Staner C, Jacob N, Nir T, Zisapel N, Staner L.
    Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
    [Abstract] [Full Text] [Related]

  • 6. Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
    Farber RH, Burke PJ.
    Curr Med Res Opin; 2008 Mar; 24(3):837-46. PubMed ID: 18257978
    [Abstract] [Full Text] [Related]

  • 7. The need for flexibility in dosing of hypnotic agents.
    Doghramji K.
    Sleep; 2000 Feb 01; 23 Suppl 1():S16-20; discussion S21-2. PubMed ID: 10755804
    [Abstract] [Full Text] [Related]

  • 8. Residual effects of sleep medication on driving ability.
    Verster JC, Veldhuijzen DS, Volkerts ER.
    Sleep Med Rev; 2004 Aug 01; 8(4):309-25. PubMed ID: 15233958
    [Abstract] [Full Text] [Related]

  • 9. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW, Suess PE, Griffiths RR.
    Arch Gen Psychiatry; 2006 Oct 01; 63(10):1149-57. PubMed ID: 17015817
    [Abstract] [Full Text] [Related]

  • 10. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M, Plosker GL.
    Drugs; 2000 Aug 01; 60(2):413-45. PubMed ID: 10983740
    [Abstract] [Full Text] [Related]

  • 11. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.
    Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, Bozigian HP, Gross RS, Gogas KR.
    J Pharmacol Exp Ther; 2004 Nov 01; 311(2):547-59. PubMed ID: 15256538
    [Abstract] [Full Text] [Related]

  • 12. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
    Evans SM, Funderburk FR, Griffiths RR.
    J Pharmacol Exp Ther; 1990 Dec 01; 255(3):1246-55. PubMed ID: 2262904
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers.
    Blin O, Micallef J, Audebert C, Legangneux E.
    J Clin Psychopharmacol; 2006 Jun 01; 26(3):284-9. PubMed ID: 16702893
    [Abstract] [Full Text] [Related]

  • 14. Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects.
    Boyle J, Wolford D, Gargano C, McCrea J, Cummings C, Cerchio K, Lines C.
    Hum Psychopharmacol; 2009 Jan 01; 24(1):61-71. PubMed ID: 18985628
    [Abstract] [Full Text] [Related]

  • 15. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.
    Drover DR.
    Clin Pharmacokinet; 2004 Jan 01; 43(4):227-38. PubMed ID: 15005637
    [Abstract] [Full Text] [Related]

  • 16. Meta-analysis of on-the-road experimental studies of hypnotics: effects of time after intake, dose, and half-life.
    Roth T, Eklov SD, Drake CL, Verster JC.
    Traffic Inj Prev; 2014 Jan 01; 15(5):439-45. PubMed ID: 24678565
    [Abstract] [Full Text] [Related]

  • 17. Highway driving in the elderly the morning after bedtime use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo.
    Leufkens TR, Vermeeren A.
    J Clin Psychopharmacol; 2009 Oct 01; 29(5):432-8. PubMed ID: 19745642
    [Abstract] [Full Text] [Related]

  • 18. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
    Zammit GK, Corser B, Doghramji K, Fry JM, James S, Krystal A, Mangano RM.
    J Clin Sleep Med; 2006 Oct 15; 2(4):417-23. PubMed ID: 17557470
    [Abstract] [Full Text] [Related]

  • 19. Zolpidem and triazolam interact differentially with a delay interval on a digit-enter-and-recall task.
    Rush CR, Baker RW.
    Hum Psychopharmacol; 2001 Mar 15; 16(2):147-157. PubMed ID: 12404585
    [Abstract] [Full Text] [Related]

  • 20. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.
    Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A.
    J Clin Psychopharmacol; 2002 Dec 15; 22(6):576-83. PubMed ID: 12454557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.